Presentation is loading. Please wait.

Presentation is loading. Please wait.

Adjuvant Surgery after Carboplatin and VP16 in Resectable Small Cell Lung Cancer  Giulia Veronesi, MD, Paolo Scanagatta, MD, Francesco Leo, MD, Tommaso.

Published byLucas Viklund Modified over 5 years ago

Similar presentations

Presentation on theme: "Adjuvant Surgery after Carboplatin and VP16 in Resectable Small Cell Lung Cancer  Giulia Veronesi, MD, Paolo Scanagatta, MD, Francesco Leo, MD, Tommaso."— Presentation transcript:

1 Adjuvant Surgery after Carboplatin and VP16 in Resectable Small Cell Lung Cancer 
Giulia Veronesi, MD, Paolo Scanagatta, MD, Francesco Leo, MD, Tommaso De Pas, MD, Giuseppe Pelosi, MD, PhD, Gianpiero Catalano, MD, Sara Gandini, ScD, Filippo De Braud, MD, Lorenzo Spaggiari, MD, PhD  Journal of Thoracic Oncology  Volume 2, Issue 2, Pages (February 2007) DOI: /S (15)30040-X Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Overall (Kaplan–Meier) survival in 23 SCLC patients.
Journal of Thoracic Oncology 2007 2, DOI: ( /S (15)30040-X) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Kaplan–Meier survival according to pathological stage in 23 SCLC patients. Stage 0 and I patients had significantly better (p = log-rank test) survival than stage II and III patients. Journal of Thoracic Oncology 2007 2, DOI: ( /S (15)30040-X) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 Disease-free survival curve in 23 patients with SCLC.
Journal of Thoracic Oncology 2007 2, DOI: ( /S (15)30040-X) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

5 FIGURE 4 Cumulative probability of relapse according to pathological stage in 23 patients with SCLC. Patients with pathological stage 0 or I had a significantly lower relapse rate than those at stage II or III. Journal of Thoracic Oncology 2007 2, DOI: ( /S (15)30040-X) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Adjuvant Surgery after Carboplatin and VP16 in Resectable Small Cell Lung Cancer  Giulia Veronesi, MD, Paolo Scanagatta, MD, Francesco Leo, MD, Tommaso."

Similar presentations

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.
Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,
Is lung cancer resection indicated in patients with idiopathic pulmonary fibrosis?  Atsushi Watanabe, MD, PhD, Tetsuya Higami, MD, PhD, Syunsuke Ohori,

Is lung cancer resection indicated in patients with idiopathic pulmonary fibrosis?  Atsushi Watanabe, MD, PhD, Tetsuya Higami, MD, PhD, Syunsuke Ohori,
Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus  Yang Zhao, MD, ZhiJun Dai,

Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus  Yang Zhao, MD, ZhiJun Dai,
Neoadjuvant Chemotherapy for Stage III and IVA Thymomas: A Single-Institution Experience with a Long Follow-up  Marco Lucchi, MD, Franca Melfi, MD, Paolo.

Neoadjuvant Chemotherapy for Stage III and IVA Thymomas: A Single-Institution Experience with a Long Follow-up  Marco Lucchi, MD, Franca Melfi, MD, Paolo.
Effect of tumor size on prognosis in patients with non–small cell lung cancer: The role of segmentectomy as a type of lesser resection  Morihito Okada,

Effect of tumor size on prognosis in patients with non–small cell lung cancer: The role of segmentectomy as a type of lesser resection  Morihito Okada,
Difficulties encountered managing nodules detected during a computed tomography lung cancer screening program  Giulia Veronesi, MD, Massimo Bellomi, MD,

Difficulties encountered managing nodules detected during a computed tomography lung cancer screening program  Giulia Veronesi, MD, Massimo Bellomi, MD,
Respiratory function changes after chemotherapy: an additional risk for postoperative respiratory complications?  Francesco Leo, MD, Piergiorgio Solli,

Respiratory function changes after chemotherapy: an additional risk for postoperative respiratory complications?  Francesco Leo, MD, Piergiorgio Solli,
Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.
Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer  Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.

Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer  Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.
Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,
Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer  Hidenobu Ishii, MD,

Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer  Hidenobu Ishii, MD,
Multimodality Treatment of Stage III Non-small Cell Lung Cancer: Analysis of a Phase II Trial Using Preoperative Cisplatin and Gemcitabine with Concurrent.

Multimodality Treatment of Stage III Non-small Cell Lung Cancer: Analysis of a Phase II Trial Using Preoperative Cisplatin and Gemcitabine with Concurrent.
The Presence of Mutations in Epidermal Growth Factor Receptor Gene Is Not a Prognostic Factor for Long-Term Outcome after Surgical Resection of Non–Small-Cell.

The Presence of Mutations in Epidermal Growth Factor Receptor Gene Is Not a Prognostic Factor for Long-Term Outcome after Surgical Resection of Non–Small-Cell.
The prognostic impact of microRNA sequence polymorphisms on the recurrence of patients with completely resected non–small cell lung cancer  Kyong-Ah Yoon,

The prognostic impact of microRNA sequence polymorphisms on the recurrence of patients with completely resected non–small cell lung cancer  Kyong-Ah Yoon,
Outcomes of unexpected pathologic N1 and N2 disease after video-assisted thoracic surgery lobectomy for clinical stage I non–small cell lung cancer  Hong.

Outcomes of unexpected pathologic N1 and N2 disease after video-assisted thoracic surgery lobectomy for clinical stage I non–small cell lung cancer  Hong.
IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology
Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non– Small-Cell Lung Cancer  Damien Urban, MBBS, B Med Sc, Jair Bar, MD, PhD,

Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non– Small-Cell Lung Cancer  Damien Urban, MBBS, B Med Sc, Jair Bar, MD, PhD,
Prognostic Factors in Completely Resected Node-Negative Lung Adenocarcinoma of 3 cm or Smaller  Jung-Jyh Hung, MD, PhD, Yi-Chen Yeh, MD, Yu-Chung Wu,

Prognostic Factors in Completely Resected Node-Negative Lung Adenocarcinoma of 3 cm or Smaller  Jung-Jyh Hung, MD, PhD, Yi-Chen Yeh, MD, Yu-Chung Wu,
Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Similar presentations

Ads by Google